BCDABioCardia, Inc.

Nasdaq biocardia.com


$ 0.40 $ 0.00 (1.23 %)    

Tuesday, 14-May-2024 15:55:52 EDT
QQQ $ 451.08 $ 2.16 (0.48 %)
DIA $ 398.50 $ 0.62 (0.16 %)
SPY $ 528.36 $ 2.43 (0.46 %)
TLT $ 92.18 $ 0.35 (0.38 %)
GLD $ 220.68 $ 1.44 (0.66 %)
$ 0.396
$ 0.39
$ 0.00 x 0
$ 0.00 x 0
$ 0.39 - $ 0.40
$ 0.32 - $ 2.92
69,049
na
10.81M
$ 0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 04-09-2020 12-31-2019 10-K
19 11-19-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 04-02-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-30-2017 12-31-2016 10-K
31 10-17-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 03-25-2016 12-31-2015 10-K
35 10-29-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-24-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-06-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biocardia-q1-eps-009-up-from-017-yoy-sales-5500k-down-from-6400k-yoy

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.09) per share. This is a 47.06 percent increase over losses of $(0.17)...

 biocardia-q4-earnings-insights
BioCardia: Q4 Earnings Insights
03/27/2024 20:10:06

 biocardia-q4-eps-009-beats-011-estimate-sales-1300k-miss-9000k-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by ...

 biocardia-ended-2023-with-cash-and-cash-equivalents-of-11m

https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=187

 earnings-scheduled-for-march-27-2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

 preview-biocardias-earnings
Preview: BioCardia's Earnings
03/26/2024 16:01:35

 biocardia-announced-a-long-term-partnership-to-advance-stemcardias-investigational-pluripotent-stem-cell-product-candidate-for-the-treatment-of-heart-failure

Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia's cell therapy candidate t...

 crude-oil-down-over-1-quoin-pharmaceuticals-shares-spike-higher

U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to ...

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

 gold-gains-1-joann-shares-plummet

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Monday. The Dow traded down ...

 biocardia-announces-activation-of-cardiamp-heart-failure-ii-phase-3-pivotal-study-recently-approved-by-fda

The Company announces activation of CardiAMP HF II, a randomized controlled pivotal trial of its CardiAMP autologous cell thera...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION